Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.59 |
| ▸ | CDK2 | P24941 | 9/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256651 | 0.92 | PTGS2 (0.68) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL6356759 | 0.89 | PTGS2 (0.64) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL6649029 | 0.84 | PTGS1 (0.48) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL6279437 | 0.81 | PTGS2 (1.00) | PTGS1PTGS2 | |
| SCHEMBL8937493 | 0.79 | PTGS2 (0.69) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL5255644 | 0.79 | CCNA2 (0.59) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL9832871 | 0.78 | PTGS1 (0.49) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL9833010 | 0.76 | PTGS1 (0.47) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL14502642 | 0.76 | CCNA2 (0.53) | PTGS1PTGS2CCNA2CDK2CCNA1 | |
| SCHEMBL2548370 | 0.76 | MAPT (0.62) | CCNA2CDK2CCNA1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | claimed |
| EP-1427706-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-06-16 | — | — | EP | claimed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| WO-2003024936-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | claimed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | PTGS1 18/4885PTGS2 22/4885CCNA2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.